Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 3

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 3
---
 sustainable growth and enhanced value creation. 5x30 Strategy for Growth and Value Creation In January 2025, we introduced our 5x30 path to becoming an innovative biopharmaceutical organization. We are confident that executing on this strategy will drive growth and value creation as a leader in musculoskeletal pain and adjacencies. The plan focuses on five key objectives that we intend to achieve by 2030: • Patients: More than three million patients treated per year • Product Revenue: Double-digit compounded annual growth rate • Profitability: Five percentage point gross margin improvement over 2024 • Pipeline: Clinical pipeline expansion with five novel programs in development • Partnerships: Establish five partnerships including pipeline and commercial agreements These objectives support two broad strategic priorities: accelerating growth in our strong commercial base business and advancing an innovative pipeline of potentially transformative assets, such as PCRX-201. In conjunction with the objectives of our 5x30 strategy, the Board of Directors and management team will continue our disciplined approach to capital allocation. As part of this approach, we initiated a share repurchase plan in 2024, and we replaced this with a new and increased authorization of $300 million in April 2025, which is authorized through December 31, 2026. We will continue to balance: • Investing in our cash-generating base business as guided by ROI metrics; • Supporting our development pipeline and innovative adjacencies; and • Applying a prudent approach to balance sheet management for the repayment of debt and return of capital to stockholders. Maximizing Commercial Opportunities As of January 1, 2025, the NOPAIN Act is in full effect, providing a reimbursement pathway for 18 million outpatient surgical procedures. Approximately six million of these procedures have CMS coverage and 12 million have commercial coverage. TABLE OF CONTENTS Additionally, EXPAREL now has its own product-specific J-code with a reimbursement rate of the average selling price plus six percent. Securing this code was a particularly important milestone as it will expand patient access to best-practice opioid-sparing care. The J-code will streamline the reimbursement and billing process and is more likely to be recognized and covered by commercial payers. Advancing an Innovative Pipeline We are fully committed to becoming the therapeutic area leader in musculoskeletal pain and adjacencies. These are large markets significantly lacking innovation. Nearly one in four Americans are living with chronic pain and are seeking new interventions to address its underlying cause. Our recently announced acquisition of GQ Bio directly aligns with our 5x30